Top-News
Biotechnologie USA

Xencor Inc News

Aktie
WKN:  A1W96L ISIN:  US98401F1057 US-Symbol:  XNCR
22,20 €
+1,40 €
+6,73%
06.05.24 16:06:01
Handeln Depot/Watchlist
Aktienanzahl *
60,88 Mio.
Marktkapitalisierung *
1,27 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 13.02.2024

Xencor Inc News

06.08.18 - PR Newswire
Xencor Reports Second Quarter 2018 Financial Results
Xencor Reports Second Quarter 2018 Financial Results - Dosed the First Patient in DUET-2, Phase 1 Clinical Trial of Lead Tumor Microenvironment (TME) Activator XmAb®20717 in ...
01.08.18 - PR Newswire
Xencor to Present at Upcoming Investor Conferences
Xencor to Present at Upcoming Investor Conferences PR Newswire
18.07.18 - PR Newswire
Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors
Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors PR Newswire
12.07.18 - PR Newswire
Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors PR Newswire
31.05.18 - PR Newswire
Xencor to Present at Upcoming Investor Conferences
Xencor to Present at Upcoming Investor Conferences PR Newswire
07.05.18 - PR Newswire
Xencor Reports First Quarter 2018 Financial Results
Xencor Reports First Quarter 2018 Financial Results -- Introduced XmAb® IL15 Bispecific Antibody Platform and Presented Preclinical Data on XmAb®24306 at American ...
30.04.18 - PR Newswire
Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018
Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018 PR Newswire
18.04.18 - PR Newswire
Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting
Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting PR ...
21.03.18 - PR Newswire
Xencor to Present at 17th Annual Needham Healthcare Conference
Xencor to Present at 17th Annual Needham Healthcare Conference PR Newswire
20.03.18 - PR Newswire
Xencor Announces Pricing of Public Offering of Common Stock
Xencor Announces Pricing of Public Offering of Common Stock PR Newswire
27.02.18 - PR Newswire
Xencor Reports Fourth Quarter and Full Year 2017 Financial Results
Xencor Reports Fourth Quarter and Full Year 2017 Financial Results -- Broadening Tumor Microenvironment (TME)-Targeting Bispecific Pipeline with XmAb®24306, Targeting IL-...
22.02.18 - PR Newswire
Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors
Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal ...
20.02.18 - PR Newswire
Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018
Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018 PR Newswire
07.02.18 - PR Newswire
Xencor to Present at Upcoming Investor Conferences
Xencor to Present at Upcoming Investor Conferences PR Newswire
05.01.18 - PR Newswire
Xencor Announces 2018 Priorities and Expected Milestones
Xencor Announces 2018 Priorities and Expected Milestones PR Newswire
19.12.17 - PR Newswire
Xencor Appoints Richard Ranieri to Board of Directors
Xencor Appoints Richard Ranieri to Board of Directors PR Newswire
08.11.17 - PR Newswire
Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer (SITC) 2017 Annual ...
07.11.17 - PR Newswire
Xencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update
Xencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update -- Announced Final Results from Phase 2 Trial of XmAb®5871 in IgG4-Related Disease ...
04.11.17 - PR Newswire
Xencor Presents Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2017 Annual Meeting
Xencor Presents Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2017 Annual Meeting - 12 of 15 ...
01.11.17 - PR Newswire
Xencor to Present at Upcoming Investor Conferences
Xencor to Present at Upcoming Investor Conferences PR Newswire

Newssuche

Videos

newspaper
07.05.24 +6,80%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »